The article profiles Cytos Biotechnology AG, a biopharmaceutical company focused on the development of targeted immunotherapies, and offers information on its products and services, and its management team including executive chairman Thomas Hecht.EBSCO_bspCytos Biotechnology Ag Medtrack Company Profile...
Amit Sharma (International Centre for Genetic Engineering and Biotechnology (ICGEB), Delhi, India) for providing the 3D7A parasite strain and Dr. Pankaj Alone (National Institute for Science Education and Research (NISER), Bhubaneshwar, India) for providing the Sui1 antibody. We thank Genotypic ...
Kuros Biosciences AG 1.424 0.000(0.00%) 1日 1周 1个月 3个月 6个月 1年 5年 最大值 YTSN评分 公司稳健度解锁 公允价值解锁价格 公允价格 看涨 技术分析 暂不支持。 分析师观点 暂不支持。 成员看法 看空 看多 ProTips 暂不支持。 关键数据 编辑 更多YTSN数据指标 卖价/买价 1.595 / 1.60 昨收...
Assignee: Cytos Biotechnology AG (Zürich-Schlieren, CH) Novartis Pharma AG (Basel, CH) Primary Class: 424/158.1 Other Classes: 424/192.1, 424/193.1, 424/194.1, 424/195.11, 424/196.11, 424/198.1, 424/278.1, 424/281.1, 424/282.1, 424/400 International Classes: A61K39/00; A61K39/385...
Biotechnology Health & Hospitals Chemical Manufacturing Consumer Packaged Goods Pharma Authors G. Weitzel (1) F. Schneider (1) Anna-Maria Fretzdorff (1) Author Affiliations 1. Physiologisch-chemisches Institut der Universität Tübingen, Deutschland Continue...
Assignee: Cytos Biotechnology AG Primary Class: 424/186.1 Other Classes: 435/5, 435/6.14, 435/7.9, 435/287.2 International Classes: A61K39/00; A61K35/76; A61K38/00; A61K39/02; A61K39/12; A61K39/29; A61K39/35; A61K39/385; A61K39/39; A61K47/48; A61P25/28; A61P29/00...
Biotechnology Electronics IT & Software Telecommunications Consumer Packaged Goods Aerospace Engineering Authors P. Stieg (1) I. Strömberg (1) L. Olson (1) Author Affiliations 1. Department of Histology and Neurobiology, Karolinska Institute, Box 60400, S-104 01, Stockholm, Sweden...
Cytos Biotechnology AG ernennt Dr. Christian Itin zum Chief Executive Officer
Sheridan, Cormac
生物技术产品抗感染作用感染性疾病技术平台表达克隆奥地利奥地利公司Intercell AG已经与位于瑞士的Cytos Biotechnology公司签订了一项协议,以获得该公司的单克隆抗体开发技术平台.该项技术的基础是来源于人类B细胞的单克隆抗体的表达克隆,并且能够用来确认具有抗感染作用的抗体,以预防和治疗感染性疾病.无不详国外药讯...